Mediterranean Journal of Hematology and Infectious Diseases (Jun 2023)

FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.

  • Daniele Avenoso,
  • Amal Alabdulwahab,
  • Michelle Kenyon,
  • Varun Mehra,
  • Pramila Krishnamurthy,
  • Francesco Dazzi,
  • Ye Ting Leung,
  • Sandra Anteh,
  • Mili Naresh Shah,
  • Andrea Kuhnl,
  • Robin Sanderson,
  • Piers Patten,
  • Deborah Yallop,
  • Antonio Pagliuca,
  • Victoria Potter

DOI
https://doi.org/10.4084/MJHID.2023.041
Journal volume & issue
Vol. 15, no. 1

Abstract

Read online

Background: The second decade of this millennium was characterized by a widespread availability of chimeric antigen receptor T-cell (CAR-T)therapies to treat relapsed and refractory lymphomas. As expected, the role and indication of allogeneic haematopoietic stem cell transplant(allo-HSCT)in the management of lymphoma changed. Currently a not unneglectable proportion of patients will be considered candidate for an allo-HSCT and the debate of which transplant platform should be offered is still active. Objectives:to report the outcome of patients affected with relapsed/refractory lymphoma and transplanted following reduced intensity conditioning at King’s College Hospital, London, between January 2009 and April2021. Methods: Conditioning was with fludarabine 150mg/m2 and melphalan 140mg/m2. The graft was unmanipulated G-CSF mobilized peripheral blood haematopoietic stem cells(PBSC). Graft-versus-host disease (GVHD) prophylaxis consisted of pre-transplant Campath at the total dose of 60 mg in unrelated donors and 30 mg in fully matched sibling donors, and ciclosporin. Results: One year and five years OS were87% and79.9%, respectively and median OS was not reached. Cumulative incidence of relapse was 16%.Incidence of acute GVHD was 48%(only grade I/II); no cases of grade III/IV were diagnosed. Chronic GVHD occurred in 39% of patients. TRM was 12%, with no cases developed within day 100 and 18months after the procedure. Conclusions:The outcomes of heavily pretreated lymphoma patients are favorable with median OS and survival not reached after a median of 49months. In conclusion, even if some lymphoma subgroups can’t be treated (yet) with advanced cellular therapies, this study confirms the role of allo-HSCT as a safe and curative strategy.

Keywords